Previous Article | Next Article 
Journal of Virology, April 2000, p. 3141-3148, Vol. 74, No. 7
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Complex Effects of Deletions in the 5' Untranslated
Region of Primate Foamy Virus on Viral Gene Expression and RNA
Packaging
Martin
Heinkelein,1
Jana
Thurow,1
Marco
Dressler,1
Horst
Imrich,1
Dieter
Neumann-Haefelin,2
Myra O.
McClure,3 and
Axel
Rethwilm1,4,*
Institut für Virologie und
Immunbiologie, Universität Würzburg,
Wurzburg,1 Abteilung für
Virologie, Institut für Medizinische Mikrobiologie und Hygiene,
Universität Freiburg, Freiburg,2 and
Institut für Virologie, Medizinische Fakultät Carl
Gustav Carus, Technische Universität Dresden,
Dresden,4 Germany, and Jefferiss
Research Trust Laboratories, Imperial College of Medicine at St.
Mary's, London, United Kingdom3
Received 16 September 1999/Accepted 27 December 1999
 |
ABSTRACT |
Due to various advantageous features there is current interest in
retroviral vectors derived from primate foamy viruses (PFVs). Two
PFV cis-acting sequences have been mapped in the 5' region of the RNA (pre-)genome and in the 3' pol genomic
region. In order to genetically separate PFV packaging constructs from
vector constructs, we investigated the effect of deletions in the 5'
untranslated region (UTR) of PFV packaging constructs and vectors on
gene expression and RNA incorporation into viral particles. Our results
indicate that the 5' UTR serves different previously unknown functions. First, the R region of the long terminal repeat was found to be required for PFV gag gene expression. This regulation of
gene expression appeared to be mainly posttranscriptional. Second, constructs with sequence deletions between the R region and the gag gene start codon packaged as much viral mRNA into
particles as the undeleted construct, and RNA from such a
5'-UTR-deleted packaging construct was copackaged into vector-virus
particles, together with vector RNA which was preferentialy packaged.
Finally, in the U5 region a sequence was identified that was required
to allow cleavage of the Gag precursor protein by the pol
gene-encoded protease, suggesting a role of RNA in PFV particle
formation. Taken together, the results indicate that complex
interactions of the viral RNA, capsid, and polymerase proteins take
place during PFV particle formation and that a clear separation of PFV
vector and packaging construct sequences may be difficult to achieve.
 |
INTRODUCTION |
Foamy viruses constitute the most
divergent genus in the family Retroviridae. The primate
foamy virus (PFV) replication strategy differs fundamentally from all
other retroviruses and appears to bridge the retroviral and
hepadnaviral replication pathway (for a recent review, see reference
31). PFVs have a genomic structure similar to other
retroviruses and require provirus integration for replication (14,
42). However, the way in which polymerase protein is expressed
(13, 57), the mode of viral capsid assembly and interaction
with the cognate envelope (Env) glycoprotein (4, 18, 19,
41), and the time point of reverse transcription in the viral
life cycle (35, 58) are unique among retroviruses and show
functional analogies to hepadnaviruses (37).
PFVs have been suggested as good candidates from which to develop viral
vectors, and several vectors are currently under construction for gene
transfer purposes (9, 15, 21, 26, 38, 45, 47, 55, 56). A
retroviral vector system consists of the vector proper, which harbors
all elements in cis required for genome packaging, reverse
transcription, integration, and transgene expression, and a packaging
cell line, which supplies in trans the viral structural and
enzymatic proteins required to execute these functions (34).
Ideally, there is little genetic overlap between vector and packaging
construct sequences to reduce the problem of generating
replication-competent virus following recombination events
(34).
In general, retroviruses harbor a cis-acting sequence
(psi in murine retroviruses) in the 5' untranslated region
(UTR) of the genome which facilitates the dominant package of genomic
viral RNA (8, 32). This sequence can usually be deleted from
the packaging constructs expressing the Gag and Pol proteins (25, 34). In PFVs the Pol protein is expressed from a spliced RNA which uses the major splice donor (SD) located at position +53 following the start of transcription (+1) and a splice acceptor located
in the gag gene (+1,850) (27, 57). Therefore, the deletion of the SD site from PFV packaging constructs and expression of
Pol protein from a separate construct may disturb a balanced expression
of Gag and Pol proteins, provided this is essential for optimal vector
production. Furthermore, it has recently been shown that PFV vectors
essentially require, besides a sequence in the 5' region of the
(pre-)genomic RNA (cis-acting sequence I [CASI]),
essentially a second sequence located in the 3' pol gene
(CASII) in order to transfer successfully marker genes (15, 21,
55). Deletion of CASII from vector constructs largely reduced the
viral RNA content of particles and also influenced the function of the
pol-encoded protease to cleave the Gag precursor protein
(21). This suggested complex interactions between the Gag
and Pol proteins and the (pre-) genomic RNA in forming a functional PFV
capsid. Since CASII is located in a coding region which cannot be
deleted from packaging constructs, we aimed to investigate deletions in
CASI to achieve separation of vector sequences from packaging sequences.
To do this, we used molecular clones of an isolate that was reported to
be obtained from human material (1). Since there is a lack
of evidence for authentic human foamy viruses (2, 44, 49),
the origin of this isolate most probably related to an incidental
trans-species transmission from chimpanzees harboring virtually identical PFVs (22, 23, 48).
 |
MATERIALS AND METHODS |
Cells.
Human fibrosarcoma (HT1080) and 293T (11)
cells were cultivated in Dulbecco modified Eagle minimal essential
medium supplemented with 10% fetal calf serum and antibiotics.
Recombinant DNA.
The plasmids pCgp-1, pCpol-2, and pCenv-1,
directing the expression of PFV Gag and Pol, Pol, and Env proteins,
respectively, under the transcriptional control of the human
cytomegalovirus (CMV) enhancer-promoter, as well as the vector pMH5/M54
and the plasmid pSP/HFV-2, which was used to generate in vitro RNA
transcripts, have been described previously (21). The pMH
vectors contain the internal green fluorescent protein (GFP) expression
cassette under transcriptional control of the spleen focus-forming
virus U3 region (6). The plasmid pMH104 was derived from
pMH5/M54. In addition to the pol gene ATG downmutation, in
pMH104 the initiation sequences of the gag gene was changed
from ATG'GCT'TCA to TTG'GCT'TAA, and thus the expression of Gag protein
ablated. This mutation and all further mutants in the 5' UTR in the
background of the gag and pol expression plasmid
pCgp-1 and the vector pMH5/M54 (as shown in detail in the figures) were
generated by recombinant PCR (24). All mutations were
verified by automated DNA sequence analysis of the amplicon by using
AmpliTaq FS and the ABI 310 sequence analysis system (Perkin-Elmer) to
exclude unwanted nucleotide exchanges.
The plasmid pSP/HFV-3 contains a part of the PFV gag gene
(5' of the NcoI restriction site) and the 5' UTR inserted in
antisense direction downstream of the SP6 promoter in the vector pSP65.
Transfections and analysis of vector transfer efficiency.
All transfections were carried out by using a calcium-phosphate
cotransfection protocol, essentially as described previously (18,
21, 29) with a total of 27 µg of plasmid DNA per 1.8 × 106 cells. Virus from pMH104 vector (9 µg) was produced
by cotransfection with gag and pol (pCgp) and
env (pCenv-1) expression constructs (9 µg each) into 293T
cells. When only one or two plasmids were transfected, the total DNA
amount was adjusted to 27 µg by using pcDNA plasmid (Invitrogen). The
vector transduction efficiency was determined as described previously
(21). Briefly, 48 h after transfection 1 ml of
cell-free supernatant (0.45-µm [pore-size] filtrate) was added to
HT1080 recipient cells, which were seeded at a density of 3 × 103 cells per well in 24-well plates 1 day before. The
cells were monitored for GFP expression 3 days after transduction by
flow cytometry on a FACScan using the LysisII and CellQuest software packages (Becton Dickinson). The transduction efficiency was expressed as the percentage of GFP-positive cells in relation to the total number
of cells analyzed.
Protein analysis.
Lysates from transfected cells or from
cell-free virus were prepared by resuspension in detergent containing
buffer, as described elsewhere (20). Cell-free virus was
obtained by filtration of supernatant from transfected cells through a
0.45-µm (pore-size) filter (Schleicher & Schuell) and subsequent
sedimentation through a 20% sucrose cushion in TNE (100 mM Tris-HCl,
100 mM NaCl, 1 mM EDTA; pH 8.0) for 3 h in an SW41 rotor (Beckman)
at 25,000 rpm and 4°C. The samples were subjected to electrophoresis
through sodium dodecyl sulfate-8% polyacrylamide gels and semi-dry
blotted onto nitrocellulose membranes (Schleicher & Schuell). The blots were incubated with rabbit antisera raised against recombinant PFV Gag
(20) and RNase H proteins (28) or, alternatively, with a mouse monoclonal antibody directed against PFV Pol protein (H. Imrich, M. Heinkelein, and A. Rethwilm, unpublished data), and were
developed by using the ECL detection system (Amersham).
RPA.
All RNase protection analyses (RPAs) were performed by
using the Direct Detection or the pTRI-GAPDH human kits from Ambion, essentially as described by the manufacturer. For the detection of RNA
in virions, virus was produced as described previously (21).
For the detection of cellular RNA by RPA, total RNA was prepared
48 h following transfection with the RNEasy Mini Kit (Qiagen), and
5 µg of RNA was used per assay. In some experiments virions were
treated with 20 µg RNase A (Sigma) per ml at 25°C for 30 min prior
to RNA extraction, and cellular RNA was treated with 0.5 U of RQ1 DNase
(Promega) at 37°C for 25 min. Antisense RNA probes were generated in
vitro from XbaI-linearized pSP/HFV-3 plasmid and
HindIII-linearized pSP/HFV-2 plasmid (21).
 |
RESULTS |
Sequences in the R region of the long terminal repeat (LTR) are
required for Gag expression.
The 5' SD of PFV, which is used to
generate the subgenomic pol, env, and accessory
gene transcripts, is located at position +53 following the
transcriptional start (+1) of the viral RNA (33, 36). A
difference from the previously published PFV sequence (33)
is due to two additional nucleotides found upon resequencing our
molecular clones. This revealed the sequence 5'-GAGCTCTCTTCACTA following the start of transcription. We assumed that sequences downstream from the SD and upstream of the gag gene (the gag
ATG is located at position +448) may be dispensable for PFV gene
expression. Deletion mutants in this region downstream of the SD (3' of
position +65) were generated in a CMV enhancer-promoter-directed
expression construct, as shown in Fig.
1A. 293T cells were transfected with these constructs and analyzed for intracellular expression of Gag and
Pol proteins. With the wild-type construct, pCgp-1, expression of the
127-kDa Pol precursor, the 80-kDa reverse transcriptase (RT) cleavage
product, the 74-kDa Gag precursor, and the 70-kDa amino-terminal
cleavage product were readily observed (Fig. 1B). Deletion of the
sequences +65 to +444 in pCgp-2 completely abolished PFV protein
expression (Fig. 1B). While the deletion of the leader sequences
downstream of the R-U5 region in pCpg-3 (
350-444) had no influence
on Gag and Pol protein expression, the deletion of sequences in R-U5
(
65-345) in pCgp-4 affected protein expression, as did the large
deletion in pCgp-2 (Fig. 1B). To characterize further the element
required to express PFV Gag and Pol proteins, we generated additional
R-U5 deletion mutants (pCgp-5 to pCgp-8 in Fig. 1A). Absence of the U5
region in pCgp-5 (
194-345) and further deletion of 3' R sequences
in pCgp-6 (
151-345) allowed for Gag and Pol protein expression.
However, with these constructs, and in particular with pCgp-7, a
reduced level of cleaved p70gag was seen (Fig.
1B). Further truncation of R (pCgp-8;
10-345) abolished detectable
PFV pr74 Gag protein expression, while due to the absence of the 5' SD
in this construct expression of Pol proteins could not be expected
(Fig. 1B). We conclude from these experiments that sequences located in
the R region downstream of the major 5' SD (namely, in constructs
pCgp-2 and pCgp-4) are required to express PFV Gag and Pol proteins.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of deletion mutants in the 5' UTR for the
expression of Gag and Pol proteins. (A) Wild-type pCgp-1 gag
and pol expression construct and deletion mutants in the 5'
UTR. The major 5' SD, the primer binding site (pbs), and the
poly(A) signal (pA+), which was derived from the bovine
growth hormone gene and is present in the pcDNA vector (Invitrogen),
are indicated. The numbering of the deletions ( ) is relative to the
start of transcription (+1). The deletions in the constructs are marked
by stippled lines. (B) Analysis of Gag and Pol protein expression
levels in 293T cells transfected with the pCgp plasmids. Cellular
lysates were reacted with PFV Gag and Pol antibodies in an immunoblot.
M, relative molecular mass standards in kilodaltons.
|
|
To investigate whether the lack of
gag gene expression in
the deletion mutants is reflected by the level of the respective
mRNA
in the transfected cells, RPA was performed. A representative
experiment is shown in Fig.
2. No
difference in
gag mRNA expression
levels in total cellular
RNA extracted from the transfected cells
was observed between Cpg-5 and
pCgp-4; the former contains the
complete R region and is able to
generate Gag protein, while the
latter is deleted in R and unable to
express Gag (Fig.
1). Similar
results were obtained when other R
region-deleted constructs,
such as pCgp-2 and pCgp-8, were analyzed
(data not shown).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Analysis of gag-encoding RNA levels by RPA in
293T cells transfected with different gag and pol
expression constructs from Fig. 1. A total of 5 µg of total cellular
RNA was assayed per lane by using the 353-nt gag
gene-derived pSP/HFV-3 probe. For control purposes, the levels of
glyceraldehyde-3'-phosphate dehydrogenase (GAPDH) were analyzed. To
investigate the possibility that contaminating plasmid DNA from the
transfections was detected by RPA, we assayed pCgp-1 DNA at the
indicated amounts in two lanes. DNase digestion prior to RPA completely
eliminated detectable traces of plasmid DNA.
|
|
Deletion mutants in the 5' UTR package viral RNA into
particles.
In retroviral packaging constructs the deletion of
sequences within the 5' UTR (the psi sequence) disables the
packaging of the gag-pol mRNA and allows for the relatively
selective packaging of psi sequence-containing vector RNA
(34, 36). In order to investigate whether a similar approach
is feasible to separate PFV packaging construct sequences from vector
sequences, we generated the internal 5' UTR deletion mutants shown in
Fig. 3A. The constructs were made in the
pMH5/M54 vector backbone (21). This vector has a wild-type
gag gene and a pol gene ATG-to-CTG mutation
(21). Since no Pol protein is expressed from this vector
genome, immature viral pr74 Gag particles (18), which are
released from cells following cotransfection with an env
expression construct, only contain viral RNA and no viral DNA.
Therefore, the vector RNA content of the particles can be analyzed
quantitatively by RPA (21). All constructs harbored the R
region-located cis-acting sequence essential for Gag protein
expression, which was identified in the previous experiment. As shown
in Fig. 3B, similar amounts of Gag protein were expressed upon
transfection of the vectors into 293T cells. Cotransfection of an Env
expression plasmid allowed the viral particles to egress from the cells
and pellet through a 20% sucrose cushion (Fig. 3B). When the RNA
content in the particles was determined by RPA with a gag
gene-derived probe, which can hybridize only to the full-length
transcript, all particle preparations, except those derived from pMH112
(
350-444), contained roughly similar amounts of viral RNA (Fig.
3C). Quantification based on six independent experiments revealed that
in relation to pMH5/M54 the viral RNA content of particles derived from
pMH112 transfection was reduced to 33%, whereas the values for pMH114,
pMH115, and pMH93 were 124, 94, and 166%, respectively. A mild
treatment of particles with RNase A prior to RNA extraction did not
change this result significantly (data not shown).



View larger version (245861K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of the viral RNA content in particulate
material derived from vector genomes deleted in the 5' UTR. (A)
Schematic view of 5' UTR deletion constructs. The deletions are marked
by stippled lines. (B) Detection of pr74 Gag protein expressed by the
pMH vectors shown in panel A and cotransfected with an envelope
expression construct (pCenv-1) in cellular lysates and in cell-free
particulate material sedimented through a sucrose cushion. M, relative
molecular mass standard in kilodaltons. (C) RPA of viron RNA of the
particles shown in panel B using a gag gene-derived probe of
353 nt. A representative example of six experiments is shown. The
marker lane (M) contains in vitro-transcribed RNA of 353 and 246 nt.
|
|
These results show that even large deletions in the 5' UTR of PFV do
not abrogate viral RNA incorporation. Interestingly,
pMH112 had a
smaller deletion (

350-444) in the 5' UTR and, nonetheless,
packaged
less viral RNA compared to the constructs pMH115 and
pMH116, which had
larger 5' UTR deletions (

194-444 and

151-444,
respectively).
Identification of a small sequence in the U5 region that is
required for protease-mediated cleavage of the Gag protein precursor in
virions.
It has been shown previously that the incorporation of
viral RNA into PFV particles affected the cleavage of the Gag protein by the pol gene-encoded protease (21). Therefore,
the 5' UTR deleted pMH vectors were, in addition to an env
expression plasmid, also cotransfected with a pol expression
plasmid, and the Gag proteins were analyzed in cellular extracts and
extracellular particles. As shown in Fig.
4A, the triple transfection of the different vectors and pol and env encoding
plasmids resulted in roughly similar levels of intracellular pr74 Gag
precursor, pr127 Pol precursor and the p80 RT cleavage product,
respectively. Intracellular cleavage of pr74 Gag was readily observed
upon transfection of pMH5/M54 and pMH112 vectors together with pCpol-2
and pCenv-1. However, with the other constructs (pMH93, pMH114, and
pMH115) the intracellular cleavage appeared to be reduced (Fig. 4A).
The analysis of extracellular particles revealed a more drastic
pattern. Only particles derived from pMH5/M54 and pMH112 transfections unequivocally showed the characteristic doublet of pr74/p70 Gag. pMH114
and pMH115 were found to be heavily defective in Gag cleavage, despite
the presence of proteolytically active Pol protein in the transfected
cells (Fig. 4B). Of particular interest was mutant pMH93 bearing only a
29-nucleotide (nt) deletion in the 3' portion of the U5 region
(
316-344) and being readily able to incorporate viral RNA (Fig.
3C). However, this mutant was also found to be unable to allow cleavage
of the Gag precursor by the pol-encoded protease supplied in
trans (Fig. 4B). In contrast, mutant pMH112, the RNA of
which was found to have a reduced capacity to be packaged (Fig. 3),
allowed for at least partial cleavage of Gag compared with wild-type
pMH5/M54 (Fig. 4).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of the Gag and Pol expression profile in cell
extracts and extracellular particulate material from cells
cotransfected with 5' UTR-deleted PFV vectors shown in Fig. 3A and
pol and env expression constructs. A
representative example of three experiments is shown. M, relative
molecular mass standards in kilodaltons. (A) Detection of Gag and Pol
proteins in cellular lysates from transfected cells. (B) Immunoblot
analysis of Gag proteins in viral particles sedimented through a
sucrose cushion.
|
|
Use of deleted packaging constructs in vector transfer
experiments.
We next applied packaging constructs deleted in the
5' UTR in vector transfer experiments. To do this, we used packaging
constructs with maximal tolerable deletions in the 5' UTR regardless of
whether they package their own RNA. 293T cells were cotransfected with pCgp-derived gag and pol expression constructs,
together with an env expression plasmid and the pMH104
vector, which is unable to generate Gag and Pol proteins from its own
genome (Fig. 5A). Vector virus from the
cell-free supernatant was subjected to recipient HT1080 cells, which
were subsequently monitored for GFP expression. As shown in Fig. 5A,
the 5' UTR-deleted gag and pol expression constructs pCgp-9 (
192-442) and pCgp-10 (
149-442) gave rise to
similar or even higher transduction rates than the wild-type pCgp-1
expression construct. When the PFV protein profile was analyzed in
cellular extracts from cells transfected only with the packaging
plasmids, pCgp-9 and pCenv-1, a reduced level of cleaved pr74 Gag
precursor was detected despite the presence of proteolytically active
Pol protein in the cells (Fig. 5B). This defect in Gag cleavage was
much more pronounced in the corresponding viral particle preparations
centrifuged through a sucrose cushion (Fig. 5B). Interestingly,
addition of the vector genome which contained all cis-acting
sequences to the transfection mix led to the activation of the
proteolytic activity of Pol to cleave the Gag precursor and thus to the
generation of infectious vector particles (Fig. 5B).


View larger version (1551K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of the vector transduction rate and protein
profile in cellular extracts and extracellular viruses from cells
transfected with 5' UTR-deleted packaging constructs, an env
expression plasmid, and a vector genome. (A) Schematic view of pCgp
packaging and pMH104 vector constructs and vector transduction rate on
HT1080 target cells with cell-free vector virus produced by transient
cotransfection, together with the pCenv-1 plasmid in 293T cells. The
transduction rates are the means and standard variations of six
experiments. (B) PFV Gag and Pol proteins in cellular lysates and
extracellular particles centrifuged through a sucrose cushion. 293T
cells were transfected as indicated, and the viral proteins were
analyzed by immunoblot. M, relative molecular mass standards in
kilodaltons.
|
|
To investigate whether RNA from the packaging construct was copackaged
into virions, RPA was performed. As shown in Fig.
6,
the
gag mRNA of the
construct pCgp-9 was detected in particulate
material when this
packaging construct was cotransfected with
an
env expression
plasmid. This finding corroborated the result
shown in Fig.
3 on the
packaging of 5' UTR-deleted vectors. Upon
triple transfection of
packaging plasmids, together with the pMH104
vector, the majority of
the viral RNA protected was derived from
the vector genome (Fig.
6).
However, the indicative band of 195
nt, which corresponds to the
gag RNA from pCgp-9, was still present
(Fig.
6), which
indicated that this RNA was copackaged into vector
genome containing
virions. No particle-associated RNA was found
when pCgp-9 was
transfected in the absence of Env or the pMH104
vector was
cotransfected together with pCenv-1 in the absence
of a
gag-
and
pol-encoding packaging construct.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Packaging of RNA from the pCgp-9 packaging constructs
into PFV vector particles. 293T cells were transfected with the
plasmids as indicated. Viral particles were prepared from the cell-free
supernatant by centrifugation through sucrose, and the
particle-associated RNA was analyzed by RPA by using the radiolabeled
LTR-spanning pSP/HFV-2 probe (21).
|
|
 |
DISCUSSION |
For the establishment of a retroviral gene transfer vector and a
corresponding packaging cell line, constructs with little or no genetic
overlap are preferentially used (34). In PFVs, an essential
component of the vector, the CASII element, resides in a coding
sequence and is consequently present on both the vector and the
packaging construct genomes (21). We therefore aimed to
investigate the influence of deletions in CASI in PFV packaging constructs on gene expression and RNA packaging.
The R region of the LTR was found to be essential for Gag and Pol
protein expression. Since the total gag mRNA levels were unaffected by constructs from which no Gag protein expression could be
detected, the effect of the R region on gag gene expression is mainly posttranscriptional. PFVs are an exception to other complex
regulated retroviruses (10) since they encode a
transcriptional trans-activator (43) and lack a
regulatory protein acting at the posttranscriptional level
(7). PFVs make extensive use of splicing to generate at
least nine major subgenomic mRNAs which encode viral proteins
(30). However, a mechanism to regulate gene expression from
unspliced PFV RNA has so far not been identified. We hypothesize that
cis-acting sequences in the R region are required to serve
this function and may act similarly to the recently identified R
region-located elements in murine retroviruses (52).
While such a mechanism could explain the lack of gag gene
expression from R region-deleted constructs, we also found a lack of
pol gene expression from constructs deleted in the UTR from sequences 12 nt 3' of the SD, which is more difficult to explain. Thus,
pol expression was found to depend on intron sequences. The
expression of functionally active Pol protein from a cDNA clone,
pCpol-2 (21; Imrich et al., unpublished), directed
from the CMV enhancer-promoter was not influenced by the presence or absence of the cis-acting element in question, and it was
also found to be independent of simultaneous Gag protein expression (5; Imrich et al., unpublished). Pol protein
expression directed by the R region-deleted constructs described in
this study requires the generation of a spliced transcript. Usually
only six nucleotides 3' of the SD site are necessary for recognition by
the splicing machinery (40, 50, 54). However, it is not
known how the unusually spliced (27, 57) PFV pol
transcript behaves in this respect. Therefore, a lack of spliced
pol transcript following transfection of the 5' UTR-deleted
plasmids is one possible explanation for the observed phenomenon.
Clearly, the role of the R region in regulating gag and
pol gene expression needs an in-depth analysis which is
beyond the scope of this study. In this respect it may be worth
reevaluating recently published data on the expression of structural
proteins in packaging cell lines for simian foamy virus type 1 vectors (56). The constructs that were used to establish these
packaging cells were devoid of most of the R region. The R region,
however, is approximately 80% conserved amongst the PFVs
(23), and we believe this sequence to be unlikely to serve
different functions in these related viruses.
It has been described previously that a PFV vector genome, pMH38, which
was severely impaired in packaging RNA because of the deletion of
CASII, was also impaired with respect to cleavage of the Gag protein by
the pol-encoded protease (21). This left the
question as to whether viral RNA packaging was required for incorporation of the Pol protein into the viral particle
(21). We now describe a mutant, pMH93, which packages large
amounts of RNA but still fails to allow cleavage of Gag. Plasmid pMH93 has only a small deletion of 29 nt in the U5 region. This result indicates that it is not the incorporation of viral RNA as such that is
required to mediate Gag cleavage but rather the presence of specific
sequences. The deletion in pMH93 is located just 5' of the
pbs and may, therefore, influence reverse transcription of
the RNA (pre-)genome which one could assume to be a prerequisite of Gag
cleavage. However, pMH112 is deleted in most of the pbs, it
packaged less of its RNA than pMH93 and allowed at least partial cleavage of Gag. This makes it unlikely that reverse transcription must
precede Gag cleavage. Furthermore, the analysis of gag
mutants has suggested that Gag cleavage must precede reverse
transcription and not vice versa (12).
While in other retroviruses RT activation is initiated by cleavage of
the Gag-Pol precursor molecule (54, 55), the way in which
the polymerase is activated in PFV is still unresolved (5).
We did not specifically address this question. However, we found that a
vector containing the cis-acting sequences must be present
to allow Gag cleavage by the pol-encoded protease. This
indicates that at least the protease function of the PFV Pol precursor
to cleave Gag requires specific RNA sequences or structures. These
sequences are in part located in U5, and they can be deleted from
packaging constructs, since they are present on the vector genome. With
respect to the activation of the RT, it is worth mentioning that PFV
pol gene expression in the vaccinia virus system revealed
high and almost identical RT values for the wild-type pol
gene and a protease active site mutant with heterologous added template
(17; N. Fischer and A. Rethwilm, unpublished data).
Reverse transcription of the PFV pregenome, however, appears to require
specific interactions of Gag, Pol, and viral RNA. Based on this and
previous studies (12, 18, 21), we suggest a role for the
viral RNA in PFV particle formation. RNA appears to be essential to
allow for the completion of the particle formation via pr74-p70
cleavage and this cleavage, in turn, is required to allow reverse
transcription of the RNA.
With respect to viral RNA incorporation, our results show that even RNA
from 5' UTR-deleted packaging constructs was efficiently packaged. We
also found packaging construct RNA in infectious vector particles
together with the vector genome. The finding that a smaller 5' UTR
deletion was packaged less efficiently than the RNA of the larger
deletions indicates that the RNA-protein interactions may be
controlled, perhaps at the structural level, by positive- and
negative-acting 5' UTR sequences. In other retroviral vector systems
the specificity of packaging genomic over subgenomic viral RNA or even
unrelated RNA is by far less than 100% (8, 32).
Furthermore, sequences outside the 5' psi signal have been identified which support the packaging of genomic RNA and are probably
responsible for a residual packaging of subgenomic RNA in these systems
(3, 8, 32). However, other studies indicated that these
effects may be due to sequences promoting RNA stability and nuclear
export, rather than acting as additional genuine packaging sequences
(25, 39, 52). It will, therefore, be interesting to
investigate how the two foamy viral CAS elements act in concert to
allow for efficient RNA packaging and how overlapping elements in CASI,
such as the signal for RNA dimerization (16), can be distinguished. Since a definite separation of packaging construct sequences and vector sequence, which avoids the incorporation of
packaging construct RNA, may be difficult to achieve in PFV vector
systems, it is worth investigating the frequency of recombinations between suitable vector and packaging construct sequences during reverse transcription. However, even in a worst case scenario such
recombination events of transcriptional trans-activator gene (tas)- and 3' U3 region-deleted constructs are very unlikely
to generate a replication-competent virus (46).
 |
ACKNOWLEDGMENTS |
We thank Ottmar Herchenröder for critical review of the
manuscript and Rolf Flügel for the gift of Pol antiserum.
This work was supported by grants from Deutsche
Forschungsgemeinschaft (Re627/6-1), Bundesministerium für
Bildung und Forschung (01KV9817/0), Bayerische
Forschungsstiftung, Sächsisches Staatsministerium für
Umwelt und Landwirtschaft, EU (BMH4-CT97-2010), and The Wellcome Trust.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Virologie, Medizinische Fakultät Carl Gustav Carus,
Technische Universität Dresden, Gerichtsstr. 5, 01069 Dresden,
Germany. Phone: (49) 351-441-5739. Fax: (49) 351-459-3530. E-mail:
Axel.Rethwilm{at}mailbox.tu-dresden.de.
 |
REFERENCES |
| 1.
|
Achong, B. G.,
P. W. A. Mansell,
M. A. Epstein, and P. Clifford.
1971.
An unusual virus in cultures from a human nasopharyngeal carcinoma.
J. Natl. Cancer Inst.
46:299-307.
|
| 2.
|
Ali, M.,
G. P. Taylor,
R. J. Pitman,
D. Parker,
A. Rethwilm,
R. Cheingsong-Popov,
J. N. Weber,
P. D. Bieniasz,
J. Bradley, and M. O. McClure.
1996.
No evidence of antibody to human foamy virus in widespread human populations.
AIDS Res. Hum. Retrovir.
12:1473-1483[Medline].
|
| 3.
|
Aschoff, J. M.,
D. Foster, and J. M. Coffin.
1999.
Point mutations in the avian sarcoma/leukosis virus 3' untranslated region result in a packaging defect.
J. Virol.
73:7421-7429[Abstract/Free Full Text].
|
| 4.
|
Baldwin, D. N., and M. L. Linial.
1998.
The roles of pol and env in the assembly pathway of human foamy virus.
J. Virol.
72:3658-3665[Abstract/Free Full Text].
|
| 5.
|
Baldwin, D. N., and M. L. Linial.
1999.
Proteolytic activity, the carboxy terminus of Gag, and the primer binding site are not required for Pol incorporation into foamy virus particles.
J. Virol.
73:6387-6393[Abstract/Free Full Text].
|
| 6.
|
Baum, C.,
K. Ito,
J. Meyer,
C. Laker,
Y. Ito, and W. Ostertag.
1997.
The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhacer core motif, creating an exclusive target for PEBP/CBF.
J. Virol.
71:6323-6331[Abstract].
|
| 7.
|
Baunach, G.,
B. Maurer,
H. Hahn,
M. Kranz, and A. Rethwilm.
1993.
Functional analysis of human foamy virus accessory reading frames.
J. Virol.
67:5411-5418[Abstract/Free Full Text].
|
| 8.
|
Berkowitz, R.,
J. Fischer, and S. P. Goff.
1996.
RNA packaging.
Curr. Top. Microbiol. Immunol.
214:177-218[Medline].
|
| 9.
|
Bieniasz, P. D.,
O. Erlwein,
A. Aguzzi,
A. Rethwilm, and M. O. McClure.
1997.
Gene transfer using replication-defective human foamy virus vectors.
Virology
235:65-72[CrossRef][Medline].
|
| 10.
|
Cullen, B. R.
1991.
Human immunodeficiency virus as a prototypic complex retrovirus.
J. Virol.
65:1053-1056[Free Full Text].
|
| 11.
|
DuBridge, R. B.,
P. Tang,
H. C. Hsia,
P.-M. Leong,
J. H. Miller, and M. P. Calos.
1987.
Analysis of mutation in human cells by using Epstein-Barr virus shuttle system.
Mol. Cell. Biol.
7:379-387[Abstract/Free Full Text].
|
| 12.
|
Enssle, J.,
N. Fischer,
A. Moebes,
B. Mauer,
U. Smola, and A. Rethwilm.
1997.
Carboxy-terminal cleavage of the human foamy virus gag precursor molecule is an essential step in the viral life cycle.
J. Virol.
71:7312-7317[Abstract].
|
| 13.
|
Enssle, J.,
I. Jordan,
B. Mauer, and A. Rethwilm.
1996.
Foamy virus reverse transcriptase is expressed independently from the gag protein.
Proc. Natl. Acad. Sci. USA
93:4137-4141[Abstract/Free Full Text].
|
| 14.
|
Enssle, J.,
A. Moebes,
M. Heinkelein,
M. Panhuysen,
B. Mauer,
M. Schweizer,
D. Neumann-Haefelin, and A. Rethwilm.
1999.
An active human foamy virus integrase is required for viral replication.
J. Gen. Virol.
80:1445-1452[Abstract].
|
| 15.
|
Erlwein, O.,
P. D. Bieniasz, and M. O. McClure.
1998.
Sequences in pol are required for transfer of human foamy virus-based vectors.
J. Virol.
72:5510-5516[Abstract/Free Full Text].
|
| 16.
|
Erlwein, O.,
D. Cain,
N. Fischer,
A. Rethwilm, and M. O. McClure.
1997.
Identification of sites that act together to direct dimerization of human foamy virus RNA in vitro.
Virology
229:251-258[CrossRef][Medline].
|
| 17.
|
Fischer, N.,
J. Enssle,
J. Müller,
A. Rethwilm, and S. Niewiesk.
1997.
Characterization of human foamy virus proteins expressed by recombinant vaccinia viruses.
AIDS Res. Hum. Retrovir.
13:517-521[Medline].
|
| 18.
|
Fischer, N.,
M. Heinkelein,
D. Lindemann,
J. Enssle,
C. Baum,
E. Werder,
H. Zentgraf,
J. G. Müller, and A. Rethwilm.
1998.
Foamy virus particle formation.
J. Virol.
72:1610-1615[Abstract/Free Full Text].
|
| 19.
|
Goepfert, P. A.,
K. L. Shaw,
G. D. Ritter, and M. J. Mulligan.
1997.
A sorting motif localizes the foamy virus glycoprotein to the endoplasmatic reticulum.
J. Virol.
71:778-784[Abstract].
|
| 20.
|
Hahn, H.,
G. Baunach,
S. Bräutigam,
A. Mergia,
D. Neumann-Haefelin,
M. D. Daniel,
M. O. McClure, and A. Rethwilm.
1994.
Reactivity of primate sera to foamy virus Gag and Bet proteins.
J. Gen. Virol.
75:2635-2644[Abstract/Free Full Text].
|
| 21.
|
Heinkelein, M.,
M. Schmidt,
N. Fischer,
A. Moebes,
D. Lindemann,
J. Enssle, and A. Rethwilm.
1998.
Characterization of a cis-acting sequence in the pol region required to transfer human foamy virus vectors.
J. Virol.
72:6307-6314[Abstract/Free Full Text].
|
| 22.
|
Heneine, W.,
W. M. Switzer,
P. Sandstrom,
J. Brown,
S. Vedapuri,
C. A. Schable,
A. S. Khan,
N. W. Lerche,
M. Schweizer,
D. Neumann-Haefelin,
L. E. Chapman, and T. M. Folks.
1998.
Identification of a human population infected with simian foamy viruses.
Nat. Med.
4:403-407[CrossRef][Medline].
|
| 23.
|
Herchenröder, O.,
R. Renne,
D. Loncar,
E. K. Cobb,
K. K. Murthy,
J. Schneider,
A. Mergia, and P. A. Luciw.
1994.
Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV).
Virology
201:187-199[CrossRef][Medline].
|
| 24.
|
Higuchi, R.
1990.
Recombinant PCR, p. 177-183.
In
M. A. Innis, D. H. Gelfand, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, Calif.
|
| 25.
|
Hildinger, M.,
K. L. Abel,
W. Ostergat, and C. Baum.
1999.
Design of 5' untranslated sequences in retroviral vectors developed for medical use.
J. Virol.
73:4083-4089[Abstract/Free Full Text].
|
| 26.
|
Hirata, R. K.,
A. D. Miller,
R. G. Andrews, and D. W. Russel.
1996.
Transduction of hematopoietic cells by foamy virus vectors.
Blood
88:3654-3661[Abstract/Free Full Text].
|
| 27.
|
Jordan, I.,
J. Enssle,
E. Güttler,
B. Mauer, and A. Rethwilm.
1996.
Expression of human foamy virus reverse transcriptase involves a spliced pol mRNA.
Virology
224:314-319[CrossRef][Medline].
|
| 28.
|
Kögel, D.,
M. Aboud, and R. M. Flügel.
1995.
Molecular biological characterization of the human foamy virus reverse transcriptase and ribonuclease H domains.
Virology
213:97-108[CrossRef][Medline].
|
| 29.
|
Lindemann, D.,
M. Bock,
M. Schweizer, and A. Rethwilm.
1997.
Efficient pseudotyping of murine leukemia virus particles with chimeric human foamy virus envelope proteins.
J. Virol.
71:4815-4820[Abstract].
|
| 30.
|
Lindemann, D., and A. Rethwilm.
1998.
Characterization of a human foamy virus 170-kDa Env-Bet fusion protein generated by alternative splicing.
J. Virol.
72:4088-4094[Abstract/Free Full Text].
|
| 31.
|
Linial, M. L.
1999.
Foamy viruses are unconventional retroviruses.
J. Virol.
73:1747-1755[Free Full Text].
|
| 32.
|
Linial, M. L., and A. D. Miller.
1990.
Retroviral RNA packaging: sequence requirements and implications.
Curr. Top. Microbiol. Immunol.
157:125-152[Medline].
|
| 33.
|
Maurer, B.,
H. Bannert,
G. Darai, and R. M. Flügel.
1988.
Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus.
J. Virol.
62:1590-1597[Abstract/Free Full Text].
|
| 34.
|
Miller, A. D.
1997.
Development and applications of retroviral vectors, p. 437-473.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 35.
|
Moebes, A.,
J. Enssle,
P. D. Bieniasz,
M. Heinkelein,
D. Lindemann,
M. Bock,
M. O. McClure, and A. Rethwilm.
1997.
Human foamy virus reverse transcription that occurs late in the viral replication cycle.
J. Virol.
71:7305-7311[Abstract].
|
| 36.
|
Muranyi, W., and R. M. Flügel.
1991.
Analysis of splicing patterns of human spumaretrovirus by polymerase chain reaction reveals complex RNA structures.
J. Virol.
65:727-735[Abstract/Free Full Text].
|
| 37.
|
Nassal, M., and H. Schaller.
1993.
Hepatitis B virus replication.
Trends Microbiol.
1:221-228[CrossRef][Medline].
|
| 38.
|
Nestler, U.,
M. Heinkelein,
M. Lücke,
J. Meixensberger,
W. Scheurlen,
A. Kretschmer, and A. Rethwilm.
1997.
Foamy virus vectors for suicide gene therapy.
Gene Ther.
4:1270-1277[CrossRef][Medline].
|
| 39.
|
Ogert, R. A.,
L. H. Lee, and K. L. Beemon.
1996.
Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm.
J. Virol.
70:3834-3843[Abstract].
|
| 40.
|
Padgett, R. A.,
P. J. Grabowski,
M. M. Konarska,
S. Seiler, and P. A. Sharp.
1986.
Splicing of messenger RNA precursors.
Annu. Rev. Biochem.
55:1119-1150[CrossRef][Medline].
|
| 41.
|
Pietschmann, T.,
M. Heinkelein,
M. A. Heldmann,
H. Zentgraf,
A. Rethwilm, and D. Lindemann.
1999.
Foamy virus capsids require the cognate envelope protein for particle export.
J. Virol.
73:2613-2621[Abstract/Free Full Text].
|
| 42.
|
Rethwilm, A.
1995.
Regulation of foamy virus gene expression.
Curr. Top. Microbiol. Immunol.
193:1-23[Medline].
|
| 43.
|
Rethwilm, A.,
O. Erlwein,
G. Baunach,
B. Maurer, and V. T. Meulen.
1991.
The transcriptional transactivator of human foamy virus maps to the bel-1 genomic region.
Proc. Natl. Acad. Sci. USA
88:941-945[Abstract/Free Full Text].
|
| 44.
|
Rösener, M.,
H. Hahn,
M. Kranz,
J. Heeney, and A. Rethwilm.
1996.
Absence of serological evidence for foamy virus infection in patients with amyotrophic lateral sclerosis.
J. Med. Virol.
48:222-226[CrossRef][Medline].
|
| 45.
|
Russel, D. W., and A. D. Miller.
1996.
Foamy virus vectors.
J. Virol.
70:217-222[Abstract].
|
| 46.
|
Schenk, T.,
J. Enssle,
N. Fischer, and A. Rethwilm.
1999.
Replication of a foamy virus mutant with a constitutively active U3 promoter and deleted accessory genes.
J. Gen. Virol.
80:1591-1598[Abstract].
|
| 47.
|
Schmidt, M., and A. Rethwilm.
1995.
Replicating foamy virus-based vectors directing high level expression of foreign genes.
Virology
210:167-178[CrossRef][Medline].
|
| 48.
|
Schweizer, M.,
V. Falcone,
J. Gänge,
R. Turek, and D. Neumann-Haefelin.
1997.
Siman foamy virus isolated from an accidentally infected human individual.
J. Virol.
71:4821-4824[Abstract].
|
| 49.
|
Schweizer, M.,
R. Turek,
H. Hahn,
A. Schliephake,
K.-O. Netzer,
G. Eder,
M. Reinhardt,
A. Rethwilm, and D. Neumann-Haefelin.
1995.
Markers of foamy virus (FV) infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected FV prevalence in man.
AIDS Res. Hum. Retrovir.
11:161-170[Medline].
|
| 50.
|
Sharp, P. A.
1994.
Split genes and RNA splicing.
Cell
77:805-815[CrossRef][Medline].
|
| 51.
|
Swanstrom, R., and J. W. Wills.
1997.
Synthesis, assembly, and processing of viral proteins, p. 263-334.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 52.
|
Trubetskoy, A. M.,
S. A. Okenquist, and J. Lenz.
1999.
R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.
J. Virol.
73:3477-3483[Abstract/Free Full Text].
|
| 53.
|
Vogt, V. M.
1996.
Proteolytic processing and particle maturation.
Curr. Top. Microbiol. Immunol.
214:95-131[Medline].
|
| 54.
|
Wieringa, B.,
E. Hofer, and C. Weissmann.
1984.
A minimal intron length but no specific internal sequence is required for splicing the large rabbit -globin intron.
Cell
37:915-925[CrossRef][Medline].
|
| 55.
|
Wu, M.,
S. Chari,
T. Yanchis, and A. Mergia.
1998.
cis-Acting sequences required for simian foamy virus type 1 (SFV-1) vectors.
J. Virol.
72:3451-3454[Abstract/Free Full Text].
|
| 56.
|
Wu, M., and A. Mergia.
1999.
Packaging cell lines for simian foamy virus type 1 vectors.
J. Virol.
73:4498-4501[Abstract/Free Full Text].
|
| 57.
|
Yu, S. F.,
D. N. Baldwin,
S. R. Gwynn,
S. Yendapalli, and M. L. Linial.
1996.
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses.
Science
271:1579-1582[Abstract].
|
| 58.
|
Yu, S. F.,
M. D. Sullivan, and M. L. Linial.
1999.
Evidence that the human foamy virus genome is DNA.
J. Virol.
73:1565-1572[Abstract/Free Full Text].
|
Journal of Virology, April 2000, p. 3141-3148, Vol. 74, No. 7
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wiktorowicz, T., Peters, K., Armbruster, N., Steinert, A. F., Rethwilm, A.
(2009). Generation of an improved foamy virus vector by dissection of cis-acting sequences. J. Gen. Virol.
90: 481-487
[Abstract]
[Full Text]
-
Roy, J., Linial, M. L.
(2007). Role of the Foamy Virus Pol Cleavage Site in Viral Replication. J. Virol.
81: 4956-4962
[Abstract]
[Full Text]
-
Peters, K., Wiktorowicz, T., Heinkelein, M., Rethwilm, A.
(2005). RNA and Protein Requirements for Incorporation of the Pol Protein into Foamy Virus Particles. J. Virol.
79: 7005-7013
[Abstract]
[Full Text]
-
Stenbak, C. R., Linial, M. L.
(2004). Role of the C Terminus of Foamy Virus Gag in RNA Packaging and Pol Expression. J. Virol.
78: 9423-9430
[Abstract]
[Full Text]
-
Boyer, P. L., Stenbak, C. R., Clark, P. K., Linial, M. L., Hughes, S. H.
(2004). Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase. J. Virol.
78: 6112-6121
[Abstract]
[Full Text]
-
Juretzek, T., Holm, T., Gartner, K., Kanzler, S., Lindemann, D., Herchenroder, O., Picard-Maureau, M., Rammling, M., Heinkelein, M., Rethwilm, A.
(2004). Foamy Virus Integration. J. Virol.
78: 2472-2477
[Abstract]
[Full Text]
-
Heinkelein, M., Rammling, M., Juretzek, T., Lindemann, D., Rethwilm, A.
(2003). Retrotransposition and Cell-to-Cell Transfer of Foamy Viruses. J. Virol.
77: 11855-11858
[Abstract]
[Full Text]
-
Heinkelein, M., Leurs, C., Rammling, M., Peters, K., Hanenberg, H., Rethwilm, A.
(2002). Pregenomic RNA Is Required for Efficient Incorporation of Pol Polyprotein into Foamy Virus Capsids. J. Virol.
76: 10069-10073
[Abstract]
[Full Text]
-
Rinke, C. S., Boyer, P. L., Sullivan, M. D., Hughes, S. H., Linial, M. L.
(2002). Mutation of the Catalytic Domain of the Foamy Virus Reverse Transcriptase Leads to Loss of Processivity and Infectivity. J. Virol.
76: 7560-7570
[Abstract]
[Full Text]
-
Heinkelein, M., Dressler, M., Jarmy, G., Rammling, M., Imrich, H., Thurow, J., Lindemann, D., Rethwilm, A.
(2002). Improved Primate Foamy Virus Vectors and Packaging Constructs. J. Virol.
76: 3774-3783
[Abstract]
[Full Text]
-
Russell, R. A., Zeng, Y., Erlwein, O., Cullen, B. R., McClure, M. O.
(2001). The R Region Found in the Human Foamy Virus Long Terminal Repeat Is Critical for both Gag and Pol Protein Expression. J. Virol.
75: 6817-6824
[Abstract]
[Full Text]
-
Eastman, S. W., Linial, M. L.
(2001). Identification of a Conserved Residue of Foamy Virus Gag Required for Intracellular Capsid Assembly. J. Virol.
75: 6857-6864
[Abstract]
[Full Text]
-
Cain, D., Erlwein, O., Grigg, A., Russell, R. A., McClure, M. O.
(2001). Palindromic Sequence Plays a Critical Role in Human Foamy Virus Dimerization. J. Virol.
75: 3731-3739
[Abstract]
[Full Text]
-
Imrich, H., Heinkelein, M., Herchenröder, O., Rethwilm, A.
(2000). Primate foamy virus Pol proteins are imported into the nucleus. J. Gen. Virol.
81: 2941-2947
[Abstract]
[Full Text]